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Summary 
Mutations in Cu/Zn superoxide dismutase (SOD1) 
cause a subset of cases of familial amyotrophic lateral 
sclerosis. Four lines of mice accumulating one of these 
mutant proteins (G37R) develop severe, progressive 
motor neuron disease. At lower levels of mutant accu- 
mulation, pathology is restricted to lower motor neu- 
rons, whereas higher levels cause more severe ab- 
normalities and affect a variety of other neuronal 
populations. The most obvious cellular abnormality is 
the presence in axons and dendrites of membrane- 
bounded vacuoles, which appear to be derived from 
degenerating mitochondria. Since multiple lines of 
mice expressing wild-type human SOD1 at similar and 
higher levels do not show disease, the disease in mice 
expressing the G37R mutant SOD1 must arise from 
the acquisition of an adverse property by the mutant 
enzyme, rather than elevation or loss of SOD1 activity. 
Introduction 
Amyotrophic lateral sclerosis (ALS), a human motor neu- 
ron disease occurring in middle to late life, is characterized 
by the degeneration of large motor neurons of the spinal 
cord, brainstem, and motor cortex. Dysfunction and death 
of these cell populations lead to weakness, atrophy, and 
spasticity (Mulder et al., 1986; Siddique et al., 1989; Kuncl 
et al., 1992; Smith, 1992; Williams and Windebank, 1993; 
Price et al., 1994). ALS occurs in both sporadic and familial 
forms, which are clinically and pathologically similar (Hor- 
ton et al., 1976). Approximately 10% of ALS cases are 
familial; in almost all instances, the pattern of inheritance 
is as an autosomal dominant (Horton et al., 1976; Mulder 
7These authors contributed equally to this work. 
et al., 1986; Siddique et al., 1989). It is estimated that 
15%-20% of patients with autosomal dominant familial 
ALS (FALS) have missense point mutations in the gene 
encoding cytosolic Cu/Zn superoxide dismutase 1 (SOD1), 
located on chromosome 21 (Rosen et al., 1993; Deng et 
al., 1993). SODs, which also include SOD2 (a manganese- 
containing mitochondrial matrix enzyme) and SOD3 (an 
extracellular Cu/Zn SOD), constitute a system of free radi- 
cal scavengers that catalyze the formation of hydrogen 
peroxide through the dismutation of superoxide anions 
(Fridovich, 1986). SOD activity is thought to play a critical 
role in the regulation of oxidative stress and in the protec- 
tion against oxygen radical-induced cellular damage, pro- 
cesses thought o be implicated in several neurodegenera- 
tive diseases (Halliwell, 1994; Yu, 1994). 
To begin to understand how different missense SOD1 
mutations influence the behavior of the enzyme (Bowling 
et al., 1993; Rosen et al., 1993; Deng et al., 1993; Robbe- 
recht et al., 1994), SOD1 activity has been determined in 
heterozygous patients with FALS. Significant reductions 
(50%-60%) in SOD1 activities were reported in blood 
(Deng et al., 1993) and brain (Bowling et al., 1993), and 
it was proposed that reduction of SOD1 activity causes 
the pathogenesis of FALS. Consistent with this idea are 
studies using organotypic cultures of rat spinal cord; 
chronic inhibition of SOD1 causes motor neuron death 
(Rothstein et al., 1994), although cell death in this system 
is not restricted to or selective for motor neurons (J. 
Rothstein, personal communication). 
Despite this prior focus on loss of activity as the mecha- 
nism underlying human FALS, recent in vitro studies have 
demonstrated that FALS mutations how different intrinsic 
effects on enzymatic activity, and at least for some FALS 
mutations (such as the substitution of arginine for glycine 
at position 37 [G37R]), the mutant enzyme retains full spe- 
cific activity (Borchelt et al., 1994). Moreover, only a mod- 
est reduction in abundance of the G37R SOD 1 polypeptide 
was observed in lymphocytes from patients, and the poly- 
peptide present retained full specific activity (Borchelt et 
al., 1994). Neither age of onset nor rapidity of progression 
of disease correlates with SOD1 activity levels (R. H. 
Brown, personal communication); moreover, up to 2-fold 
differences in SOD1 activity are frequently detected in nor- 
mal individuals (e.g., Deng et al., 1993; Bowling et al., 
1993). These collective observations call into question the 
idea that reduction in SOD1 activity plays a critical role in 
FALS, particularly for the G37R mutation. 
To begin to analyze the mechanisms whereby the FALS- 
linked G37R mutant SOD1 causes disease in vivo, we 
have produced multiple lines of transgenic mice that ex- 
press either the human wild-type or G37R mutant SOD1 
at different levels. Four lines of mice expressing the G37R 
mutation with 5-14 times normal SOD1 activity levels in- 
variably develop the clinical phenotype of motor neuron 
disease associated with extensive vacuolation of den- 
drites and axons of motor neurons. In contrast, mice ex- 
pressing wild-type SOD1 up to 10 times the endogenous 
Neuron 
1106 
A 
B 
D 
hSOD1 gene 
codon 37 GGA--'-~AGA 
glycine arginine 
C 
b¢~ founders with MND ~ 
G37R wt m W ~ 
42 9 106 29 76 cont ro i  
h 
m 
SOdl -wt  
NM ~,o 
4,2 9 106 29 wt 
Figure 1. SOD1AccumulationinTransgenicMiceExpressingHuman 
Wild-Type or the G37R Mutant SOD1 
(A) Schematic drawing of the human wild-type SOD1 gene. The muta- 
tion to convert codon 37 from a glycine to an arginine is shown (bottom). 
(B) Number of founders generated for wild-type and mutant SOD1. 
(C) Accumulation of wild-type and mutant G37R SOD1 in transgenic 
mice. Total protein (20 ~g) extracted from various tissues of control, 
wild-type (SODl-wt-line 76), and mutant G37R (line 9) SOD1 mice 
were electrophoresed on 15% SDS-PAGE gels and immunoblotted 
using a rabbit polyclonal antibody recognizing a common epitope 
shared between the human (h) and mouse (m) SOD1, followed by 
1251-labeled protein A. 
(D) Quantitative immunoblotting of 20 Ilg of total protein extracts of 
spinal cord from wild-type line (76) and G37R lines (42, 9, 106, 29), 
using the same antibody as in (C) followed by l~l-labeled protein A. 
A series of 2-fold dilutions (not shown) of purified human SOD1 (Sigma, 
SOD1 in spinal cord did not develop weakness or histologi- 
cal abnormalit ies. These findings prove that this FALS- 
linked mutation can cause motor neuron disease in mice 
through acquisition of an adverse property by the mutant 
SOD1. These results strongly support the view that the 
human disease, at least for illness associated with this 
FALS-linked SOD1 mutation, may arise not from loss of 
SOD1 activity, but from an aberrant property of this SOD1 
mutant. 
Results 
Multiple Lines of Mice Expressing Human Wild-Type 
or G37R Mutant SOD1 
Transgenic mice were generated that carry a 12 kb geno- 
mic DNA fragment encoding human wild-type or G37R 
mutant SOD1 (Figure 1A; Epstein et al., 1987). From 138 
potential transgenic pups, 24 founders were identified for 
wild-type human SOD1; from 128 initial pups, 23 founders 
were identified with the G37R mutant (Figure 1 B). Levels of 
accumulated polypeptides were measured for all founders 
by protein immunoblott ing of whole blood using a SOD1 
antibody generated against a peptide sequence identical 
in mouse and human SOD1 (Pardo et al., 1995). Lines 
were established from four founders expressing varying 
levels of the wild-type SOD1 and from eight founders ex- 
pressing the highest levels of the G37R mutant (Table 1). 
Quantitative immunoblott ing coupled with activity as- 
says that use gel mobility to resolve human and mouse 
SOD1 revealed that, in the four wild-type lines, the human 
SOD1 protein accumulated to between 3 and 4 times the 
St. Louis, Missouri) were immunoblotted in parallel for quantitative 
analysis using a Phosphorimager. 
(E) Ratios of human to mouse SOD1 as determined by phosphorim- 
aging of data in (D). 
Table 1. Lines of Transgenic Mice Expressing Wild-Type (wt) or a Missense Mutation (G37R) in Human Sod1 
Relative SOD1 Protein 
Levels (human/mouse a) 
Line Number Blood Brain Spinal Cord 
Total SOD1 Activity 
Relative to Control 
in Spinal Cord 
Motor Neuron Disease: 
Age of Onset 
(Months) b 
wt(76) 4.0 8.0 10.5 9.2 None ° 
wt(30) 3.5 6.0 7.0 8.0 None ° 
wt(31) 3.5 ND ND ND None c 
wt(57) 3.0 N D ND ND None c 
G37R(42) 2.5 10.0 12.3 14.5 3.5-4 
G37R(9) 1.5 5.4 6.2 9.0 5-6 
G37R(106) 1.0 4.2 5.3 7.2 5.5-7.5 
G37R(29) 1.0 4.0 5.0 7.0 6-8 
G37R(50) 0.9 ND ND ND None s 
G37R(123) 0.8 ND ND ND None d 
G37R(106) 0,7 N D ND ND None d 
G37R(1) 0.5 ND ND ND None d 
a Two animals from each line were examined. 
b Determined by the reduction of stride length; at least five animals were analyzed for each of the affected G37R lines. 
° By 18 months of age. 
d By 9 months of age. 
ND, not determined. 
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Figure 2. SOD1 Enzymatic Activity in Mice Expressing Human Wild- 
Type or G37R SOD1 
SOD1 activity assay gel of spinal cord extracts (20 ilg of protein) from 
nontransgenic control (C), SOD1 wild-type lines 30 and 76, and G37R 
lines 29, 106, 9, and 42. A series of 2-fold dilutions (from 0.1 to 1.6 
p.g) of purified human erytbrocyte SOD1 was used for quantitation. 
Note that he electrophoretic migration of the mutant differs from that of 
wild-type human SOD1 in these assay gels. m, position of homodimeric 
wild-type mouse SOD1; wt-h/m, heterodimeric wild-type human/ 
mouse SOD1; wt-h, homodimeric wild-type human SOD1. 
endogenous mouse protein in blood, with a corresponding 
increase in SOD1 activities. Analyses of various tissues 
of progeny of founders disclosed high levels of expression 
in many tissues. Levels of transgene-encoded wild-type 
SOD1 in spinal cord were higher than in blood (i.e., levels 
of the transgene product [Figures 1D and 1E; Table 1] 
were between 7 and 10 times the endogenous SOD1 in 
spinal cord). In the four G37R lines expressing the highest 
SOD1 levels, the mutant polypeptide accumulated in the 
same tissues as the wild type (Figure 1C), with levels rang- 
ing from 0.5 to 2.5 times endogenous SOD1 in blood and 
from 5 to 12 times in spinal cord 0"able 1). In these mice, 
activity gels revealed a comparable increase in SOD1 
polypeptide (Figure 2; Table 1), confirming that the G37R 
mutant synthesized in vivo retains full specific activity (as 
initially demonstrated in transfected cells by Borchelt et 
al., 1994). 
To examine the distribution of transgene product in the 
nervous system, spinal cords and brains from animals that 
expressed wild-type or mutant SOD1, as well as non- 
transgenic littermates, were examined by immunocyto- 
chemistry using antibodies against SOD1. As recently re- 
ported (Pardo et al., 1995), SOD1 immunoreactivity in
normal mice was present in many neuronal populations, 
being particularly abundant in motor neurons. In nervous 
tissues of transgenic mice, patterns of SOD1 immunoreac- 
tivity showed an overall increase (data not shown) and 
mimicked that of the endogenous protein. 
Motor Neuron Disease in G37R Mice, but Not Mice 
Expressing Wild-Type Human SOD1 
The four lines of mice expressing the highest levels of the 
G37R SOD1 mutant appeared normal during the first few 
months of life but began to develop clinical signs between 
4 and 6 months of age (Table 1). Affected mice initially 
showed reduced spontaneous movement and, when lifted 
by their tails, had difficulty extending and moving their hind 
limbs. With time, the G37R-expressing mice exhibited fine 
axial tremors, asymmetric weakness of limbs, poor groom- 
ing, rough coat, and muscle wasting, particularly along 
the flanks. Eventually, the hind limbs were completely par- 
alyzed. All affected animals progressively lost weight. 
Electromyographic analysis of lumbar paraspinous mus- 
cles showed characteristic spontaneous, positive sharp 
waves associated with denervation atrophy (data not 
shown). To date, no clinical phenotype has appeared in 
the mice in the four lines expressing lower levels of the 
mutant SOD1 or in an additional 15 founder animals (9 
months of age) that accumulate the mutant to <0.5 times 
the level of the mouse SOD1 in blood. Significantly, 
transgenic lines expressing high levels of the wild-type 
human SOD1 (u p to 10-fold the endogenous in spinal cord; 
Table 1) have not exhibited any clinical or pathological 
evidence of motor neuron disease at 18 months of age. 
To evaluate the character, evolution, and distribution of 
abnormalities in the nervous system, we examined a total 
of 40 mice of various ages from the four affected G37R 
lines and nontransgenic Iittermates. All four G37R lines 
exhibited striking progressive neuropathological bnor- 
malities associated with degeneration of motor neurons 
in the ventral horns of the lumbar, thoracic, and cervical 
spinal cord, as well as motor neurons in the brain stem. 
These results are summarized in Table 2. At 5 weeks of 
age, mice from all four lines showed no indications of neu- 
Table 2. Progressive Pathology in Spinal Cord of Mice Expressing the G37R SOD1 
Line 29 Line 106 Line 9 
Age (weeks) Age (weeks) Age (weeks) 
Line 42 
Age(week~ 
11 19 35 11 " 18 27 5 10 15 17 20 11 15 18 25 
VentraHateral tract degeneration 
Dorsal root degeneration 
Ventral root degeneration 
Ventral root exit swelling and vacuolation 
Motor neuron vacuolation 
Motor neuron loss 
Neuropil vacuolation 
Reactive astrogliosis 
# # # 
* * * * * 
Spinal cords of mice at different ages from each G37R line indicated were neuropathologically evaluated. Asterisk indicates the abnormality was 
observed; pound sign indicates the few surviving motor neurons and absence of vacuoles. 
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Figure 3. Neuropathological Abnormalities in the Spinal Cord of G37R-Expressing Transgenic Mice 
(A-C) Ventral horn region of the cervical spinal cord from age-matched 20-week-old nontransgenic l ttermate (A), wild-type SOD1 (line 76; B), and 
G37R(9) transgenic mouse (C). Open arrows indicate the ventral root exit zone. Sections were stained with hematoxylin and eosin. Bar, 40 p.m. 
(D and E) Higher magnification views of the neuropil in the ventral horn of spinal cord in an 11-week-old transgenic mouse expressing the wild-type 
SOD1 (line 76; D) as compared with an age-matched G37R(42) transgenic mouse (E). The open arrow in (E) highlights vacuolation of a myelinated 
axon in the neuropil. Bars, 25 p.m. 
(F) Vacuolated perikarya of motor neurons in the ventral horn of a 11-week-old G37R(42) mouse. The open arrow points to a soma with marginal 
vacuolation and pyknotic nucleus. Hematoxylin and eosin. Bar, 20 p.m. 
(G) Ventral horn of a 17-week-old G37R(9) mouse visualized by Bielschowski silver impregnation. Open arrows point to vacuole-containing motor 
neuron cell bodies. Closed arrow denotes axonal or dendritic vacuole. Bar, 25 p.m. 
(H) Ventral horn from an 11-week-old G37R(42) transgenic mouse immunostained with antibodies against ubiquitin. Bar, 30 I~m. 
(I) Phosphorylation of neurofilaments in motor neurons from a 17-week-old G37R (9) mouse detected with an antibody (SMI-31) against a phosphory- 
lated neurofilament epitope. Small- and medium-sized arrows indicate cytologically normal motor neurons with minimal and moderate immunoreactiv- 
ity, respectively; the large arrow points to a vacuolated, degenerating neuron with marked phosphorylation of neurofilaments. Bar, 30 p.m. 
(J) Immunostaining of spinal motor neurons of a 17-week-old G37R(9) mouse with an antibody (SMI-32) recognizing a nonphosphorylated neurofila- 
ment epitope. Bar, 10 tLm. 
renal degenerat ion in the spinal cord. However, by 11 
weeks of age (lines 42 and 9), vacuoles were conspicuous 
in the ventral horn neuropil, particularly in dendrites (Fig- 
ures 3D-3F)  at all levels of the spinal cord; similar lesions 
were seen in proximal axons of motor neurons (Figures 
4A-4D). Both dendrites and axons were often focally dis- 
tended by accumulation of vacuoles. To a lesser extent, 
vacuoles appeared in perikarya of motor neurons (Figures 
3F, 3G, 31, and 3J). By 20 weeks of age, there were marked 
reductions in the number of motor neurons in the lumbar 
spinal cord (shown in Figure 3C for line 9) as compared 
with both l ittermate controls (Figure 3A) and age-matched 
transgenic mice expressing high levels of the wild-type 
human SOD1 (Figure 3B). 
Using antibodies recognizing MAP2 or phosphorylated 
neurofi laments to identify dendrites and axons, respec- 
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Figure 4. Neuropathological Abnormalities in the Root Exit and Ventral Horn Regions of the Spinal Cord in a 20-Week-Old G37R(9) Mutant Mouse 
(A and B) Swelling and vacuolation in the ventral root exit region as visualized by (A) Bielschowski-silver impregnation and (B) toluidine blue 
staining of a plastic section. Arrows in fA) denote axonal swellings; small arrows point to vacuolated swellings; long arrow points a silver positive 
swelling without apparent vacuoles. Bar, 30 p.m. 
(C) Localization of SOD1 with antibody, pAb-m/h-SOD1, recognizing both human and mouse SOD1. Closed arrows denote accumulation and 
margination of SOD1 immunoreactivity in large axons. Curved open arrows point tomarginal immunoreactivity in small axons or di tended dendrites. 
Bar, 25 p.m. 
(D) Localization of phosphorylated neurofilaments using antibody SMI-31. Arrows denote swollen, vacuolated axons with marginated neurofilament 
staining surrounding vacuoles. Bar, 25 p.m. 
(E and F) Vacuoles in dendritic (E) and a×onal (F) compartments as demonstrated by immunocytochemistry with MAP2 (E) and SMI-31 (F) antibodies. 
Open arrowheads point to regions of normal caliber of neuronal processes. Large arrowhead denotes neuronal perikaryon. Bar, 20 p.m. 
tively, vacuoles were definitively visualized in both den- 
dritic (Figure 4E) and proximal axonal (Figure 41=) compart- 
ments that showed segmental enlargement. The vacuoles 
themselves were not stained by these immunocytochemi- 
cal methods (Figures 31 and 3J; Figure 4D) nor by silver 
techniques (denoted by arrows in Figure 3G and Figure 
4A). In these immunocytochemical preparations, the mor- 
phological patterns were consistent with displacement of 
cytoskeletal elements by vacuoles in both dendrites and 
axons. Only an occasional axonal swelling was strongly 
reactive with silver (e.g., Figure 4A, central arrow). In some 
instances, a through-focal series failed to reveal underly- 
ing vacuoles in enlarged axons, suggesting that these 
silver-reactive accumulations may represent neuroflla- 
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Figure 5. Degeneration of Ventral Root Axons in G37R Transgenic 
Mice 
(A and B) L4 dorsal (DR) and ventral (VR) roots of 8-month-old 
tranegenic mice expressing (A) wild-type SOD1 (line 76) or (B) the 
G37R SOD1 mutant (line 29). Bar, 25 p_m. 
(C and D) Higher magnification views of longitudinal (C)and cross (D) 
sections of ventral roots from the G37R mouse in (B). Small arrows 
point to vacuolated axons; large arrows denote Wallerian degenera- 
tion. Bars, 25 p.m (C); 10 p_m (D). 
mentous swellings. Vacuoles in the neuronal perikarya 
distorted the appearance of the soma and changed the 
normal pattern of cytoskeletal elements (Figure 3J), includ- 
ing the appearance of detectable levels of the phosphory- 
lated neurofilament NF-H subunit in cell bodies (Figure 
31). In intermediate and late stages of degeneration, some 
neuronal perikarya and their processes were ubiquitin im- 
munoreactive (Figure 3H). An antibody (Pardo et al., 1995) 
that detects both the transgene-encoded human SOD1 
and the endogenous mouse SOD1 with equal avidity did 
not detect SOD1 within vacuoles, although it was readily 
detected in the cytoplasm surrounding the vacuoles (Fig- 
ure 4C, arrows). Moreover, SOD1 immunoreactivity was 
abundant in many of the enlarged, distorted axons of the 
intraparenchymal ventral roots. 
In more advanced stages of disease, the number of spi- 
nal motor neu rons was reduced, and there was extensive 
Wallerian degeneration of large myelinated axons at the 
level of the ventral root exit zone and motor nerve roots 
(Figures 5A-5D). In the highest expressing line G37R(42), 
some evidence of axonal degeneration was also seen in 
the dorsal roots, ascending pathways of the dorsal col- 
umns, and presumed ascending and descending fibers in 
the ventrolateral white matter of the spinal cord (data not 
shown). To date, we have not seen evidence of axonal 
degeneration in the main corticospinal tract, which in the 
mouse resides deep in the ventral portion of the dorsal 
column. In addition to these neuronal abnormalities, all 
four lines of mutant mice showed astrogliosis in the spinal 
cord. In the most thoroughly studied line, G37R(9), subtle 
astrogliosis, as visualized by the presence of GFAP immu- 
noreactivity, was present in the ventral horn as early as 
5 weeks of age (Table 2). In all four affected lines, astro- 
gliosis became more conspicuous at more advanced 
stages of disease. Analysis of two different lines of mice, 
wtSODl(76) and wtSOD1(30), expressing wild-type SOD1 
to 7 and 10 times the level of mouse SOD1 in spinal cord 
revealed no similar abnormalities, at least by 14 months 
of age, the oldest time point examined. 
In all affected G37R mice, marked loss of motor neurons 
was accompanied by evidence of denervation of muscle 
and extensive muscle atrophy. In early and intermediate 
stages of clinical disease, histochemical stains (e.g., 
NADH dehydrogenase, ATPase [pH 9.4 and 4.3], and Go- 
mori trichrome) to distinguish between fast, type 1, and 
slow, type 2, muscle fiber types demonstrated that the 
normal random distribution of fiber types (Figure 6C) was 
replaced in mutant mice by fiber type grouping (Figure 
6D) and evidence of small angulated (atrophied) fibers 
(Figures 6B and 6D, arrows). In all four affected G37R lines 
in late stages of disease, loss of motor axons, denervated 
endplates, atrophy of muscle fibers, and grouped atrophy 
were invariably observed, whereas these abnormalities 
were not evident in mice with the wild-type SOD1 
transgene. 
Mutant SOD1 Causes Mitochondrial Degeneration 
in Motor Neurons 
In all four lines of G37R mutant mice, the vacuoles were 
intracytoplasm icand were bounded by a single membrane 
(Figure 7). Moreover, vacuoles in all compartments (den- 
drites, axons, and perikarya) most frequently contained 
mitochondria in various stages of degeneration (Figures 
7A and 7B). These lesions appeared to progress from rela- 
tively mild abnormalities (Figure 7F, large open arrow) to 
mitochondria that appeared swollen with altered cristae 
(Figures 7B and 7D, closed arrows) to membranous truc- 
tures no longer definitively recognizable as mitochondria 
(Figure 7B, open arrows). In at least some cases, swellings 
appeared to originate in the intermembranous space, with 
prominent distention of the outer mitochondrial mem- 
brane, displacement of the inner membrane (Figure 7E, 
short closed arrows), and unfolding and disruption of the 
cristae (Figure 7E, large open arrow). In many instances, 
the interior of vacuoles showed multiple double membrane 
profiles (Figure 7D), as well as damaged cristae. In neu- 
ronal processes, particularly proximal axons, altered mito- 
chondria were often closely aligned in rows or closely asso- 
ciated in clusters (Figure 7C, closed arrows). Significantly, 
mitochondria in the processes of the majority of nonmotor 
neurons and in adjacent nonneuronal cells (i.e., gila) were 
uniformly unaffected (Figures 7A-7D and 7F) and were 
indistinguishable from those in normal mice or in transgenic 
lines expressing high levels of wild-type SOD1. 
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Figure 6. Striated Muscle from Control and Mutant G37R 42 Transgenic Mice 
Gomori-trichrome (Aand B) and NADH histochemistry (C and D) of muscle fibers from an 11-week-old nontransgenic mouse (A and C) and an 
age-matched G37R(42) mouse (B and D). Arrows denote group atrophy. In (C) and (D), type-I muscle fibers stain darkly; type-II fibers stain lightly. 
Bars, 35 ~m (A and B); 70 p.m (C and D). 
High Levels of the G37R Mutant Cause Pathology 
Beyond the Motor System 
To assess whether other neuronal types were affected by 
the G37R SOD1 mutant, we examined many other regions 
of the central nervous ystems of G37R mutant mice. In 
all four affected G37R transgenic lines, abnormalities simi- 
lar to those in the spinal cord were discernible in perikarya, 
axons, and dendrites of brainstem motor neurons in cra- 
nial nerve nuclei (including V, VII, X, and XII; Table 3). In 
the two affected lines expressing the lowest level of mutant 
SOD1, G37R(106) and G37R(29), pathology was re- 
stricted to motor neurons in the spinal cord and brainstem. 
However, in animals from lines showing increased levels 
of the mutant protein, widespread degenerative changes 
were observed in other populations ofneurons (Table 3). In 
the spinal cords of the highest expressing line, G37R(42), 
some vacuolization was present in the neuropil of the sub- 
stantia gelatinosa (primary sensory inputs) and scattered 
in some of the fiber tracts of the ventral and lateral white 
matter of the spinal cord. The G37R mutant mouse lines 
did not show degeneration in the murine equivalent of 
the human corticospinal tract. In lines G37R(42 and 9), 
vacuolar lesions were also present in olfactory bulb, in 
piriform cortex, in several thalamic nuclei, in a subset of 
neurons in the pons, and in cerebellar oof nuclei (summa- 
rized in Table 3). 
In addition, in the higher expressing lines G37R(42 and 
9), vacuoles were also observed in nonneuronal cells, in- 
cluding epithelial cells of the choroid plexus and the proxi- 
mal tubules of the kidney (Table 3). Despite high levels 
of expression of the mutant SOD1 in mitochondria-rich 
cardiac and skeletal muscle, vacuoles couJd not be visual- 
ized at the light microscopic level in either of these tissues. 
Discussion 
The present investigation has established that multiple 
lines of transgenic mice expressing different levels of the 
FALS-linked G37R mutant SOD1 protein develop several 
of the principle clinical nd pathological hallmarks of ALS, 
despite significantly elevated free radical scavenging ac- 
tivity. Multiple lines of mice accumulating similar or higher 
levels of the wild-type SOD1 in indistinguishable tissue 
distributions do not exhibit clinical signs (at least by 18 
months of age) or pathology (at least by 14 months of age). 
These findings prove that disease in the affected G37R 
mice is mediated by a gain of an adverse property associ- 
ated with this FALS-linked SOD1 mutation. An earlier re- 
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Figure 7. Ultrastructural Characteristics of Vacuolar Degeneration of the Ventral Horn and Axons of the Ventral Root Exit in G37R Transgenic 
Mice 
(A and B) Distended endrites containing vacuoles. Closed arrowheads denote margination and degeneration of mitochondria. Open arrows point 
to membranous profiles inside vacuoles (B). Curved arrow denotes a synaptic contact; the asterisk indicates the dendritic cytoskeleton. Bars, 150 
nm (A); 100 nm (B). 
(C and D) Vacuolation of large myelinated axons in the root exit region. Arrows point to degenerating mitochondria; the asterisk indicates displaced 
axoplasm; open arrows in (D) denote double-membrane profiles. Bars, 200 nm (C); 300 nm (D). 
(E) Degenerating mitochondria in a myelinated axon. The open arrow indicates early stage of degeneration showing (small closed arrow) splitting 
of the outer and inner membranes. The curved closed arrow points to an intermediate stage of degeneration with marked distention of the outer 
membrane and separation and disruption of the inner membrane and cristae inside. Bar, 200 nm. 
(F) Vacuole inside a degenerating dendrite. The large open arrow indicates attachment of a degenerating mitochondrion to the vacuolar membrane 
(curved arrows) and disruption of the cristae. The profile of other membranes presumably from mitochondria re also present. The x indicates 
skeins of glial fibers in an adjacent astrocyte. Straight closed arrows denote the dendritic membrane. Bar, 200 nm. 
port (Gurney et al., 1994) of similar disease in one line of 
mice with elevated levels of SOD1 activity as the result 
of expressing a different FALS-associated mutation (G93A) 
is also consistent with a gain of adverse property, although 
McCord (1994) has noted that disease in this one line could 
arise from an unusual pattern or level of transgene expres- 
sion. Our results with the G37R mutant, in concert with sev- 
eral studies of transgenic mice expressing high levels of 
wild-type human SOD1 (see below), lend further support 
to the hypothesis, initially proposed by Gurney et al. 
(1994), that the G93A SOD1 mutant acquires an abnormal 
property. Moreover, the finding in one additional mouse 
line that expression of a point mutant in mouse SOD1 
causes disease apparently without elevation in SOD1 ac- 
tivity (Ripps et al., 1995) is also consistent with a gain of 
adverse property for this SOD1 mutant. 
A key unresolved question is whether the gain of ad- 
verse property that causes motor neuron disease in mice 
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Table 3. Increasing Levels of Expression of G37R Mutant SOD1 
Cause Vacuolization outside the Motor System 
G37R Line Number 
29 106 9 42 
Brain Region 
Hippocampus 
Striatum 
Thalamus 
Hypothalamus 
Somatosensory cortex 
Pyriform cortex 
Olfactory bulb 
Choroid plexus 
Organ .
Lung 
Heart 
Liver 
Spleen 
Kidney 
Pancreas 
m 
m 
m 
m 
D 
m 
m 
m 
m m 
m R 
+ + 
+ ++ 
+ ++ 
+ ++ 
+ ++ 
+ ++ 
- -  m 
m 
_ m 
+ + 
+, mild-to-moderate vacuolar changes; ++, marked vacuolar changes. 
" Based on light microscopic examination. 
expressing high levels of the G37R mutant SOD1 also 
underlies disease in FALS, in which no evidence suggests 
increased expression of the mutant subunit. However, we 
would emphasize that the G37R mutant is both present 
(at a slightly reduced level) and active in lymphocytes from 
patients with FALS (Borchelt et al., 1994); hence, available 
evidence is not consistent with the idea that human dis- 
ease linked to this mutation could arise from a loss-of- 
function mechanism. Our observations trengthen the in- 
ference that a similar mechanism, i.e., an adverse property 
of the mutant SOD1, may mediate motor neuron disease 
in both mice and humans. Moreover, as inherent activity of 
the various FALS-linked SOD1 mutants does not correlate 
either with age of onset or speed of progression of human 
disease (R. H. Brown, personal communication), it is plau- 
sible that many, possibly all, of the FALS-linked SOD1 
mutations cause disease, not by diminution of activity, but 
by the acquisition of an adverse property. 
Another finding of relevance to the mechanism of dis- 
ease is that, to date, chronic accumulation of up to 10-fold 
higher than normal levels of wild-type SOD1 activity in 
many tissues of mice from divergent genetic backgrounds 
does not produce a FALS-like motor neuron disease (Ep- 
stein et al., 1987; Avraham et ai., 1988; Gurney et al., 
1994; Ripps et al., 1995; the present report). Though the 
in vivo consequences of reduction in SOD1 activity are not 
yet established experimentally, these independent reports 
demonstrate that chronic increase in SOD1 does not result 
in disease. Hence, at least with respect to elevation in 
SOD1, this disproves the hypothesis (McCord, 1994; Nel- 
son et al., 1994) that maintenance of a very tightly regu- 
lated balance of enzymes in free radical metabolism is 
essential for a normal phenotype. 
As to the nature of the aberrant property gained by the 
mutant SODls, likely choices are Cu toxicity or disruption 
in intracellular Cu homeostasis. Catalysis by SOD1 is me- 
diated by an active site Cu molecule, which the wild type 
enzyme binds with high affinity. Moreover, wild-type SOD1 
is among the most stably folded polypeptides known, with 
the homodimers remaining folded and Cu bound even in 
8 M urea. An essential metal, free Cu catalyzes conversion 
of superoxide to hydrogen peroxide as efficiently as SOD1 
(Sawyer and Valentine, 1981) but is also highly toxic. Muta- 
tions almost certainly lower the stability of folding and the 
in vivo half life (e.g., Borchelt et al., 1994); this may result 
in the mutant polypeptide failing to bind or shield the Cu 
as effectively as the wild type. The less fully sheltered Cu 
and subsequent reaction of the reduced Cu with hydrogen 
peroxide could enhance production of hydroxyl radicals, 
which could then attack sites near the location of the metal 
(Korbashi et al., 1989; Stadtman, 1990). In this model, 
whether a mutant SOD1 retained activity as a superoxide 
dismutase would be irrelevant; rather, the key feature 
would be the gain of Cu-mediated toxicity. One potential 
specific example of a Cu-dependent, gain of adverse prop- 
erty would be an increase in enzyme catalyzed nitration 
of protein-bound tyrosines using peroxynitrite formed from 
spontaneous reaction of superoxide with nitric oxide 
(Beckman et al., 1993). 
A mechanism of disease mediated by disruption in intra- 
cellular Cu trafficking is also supported by emerging ge- 
netic evidence in yeast that demonstrates a close relation- 
ship between SOD1 and metal homeostasis. Absence of 
SOD results in a slow growth phenotype in atmospheric 
oxygen (Liu et al., 1992). Two unbiased genetic screens 
have identified three genes that genetically interact with 
SOD1 and that complement he aerobic growth defect aris- 
ing from absence of SOD1. Remarkably, all three gene 
products influence the intracellular trafficking of Cu. Muta- 
tion in either the BSDIlPMR1 gene, encoding a putative 
metal transport protein that localizes to the Golgi (Lap- 
inskas et al., 1995), or in BSD2, encoding a 37 kDa protein 
that functions in Cu ion detoxification (Liu and Culotta, 
1994), restores near normal growth in the absence of 
SOD1. Similarly, increased expression of the ATXl gene, 
encoding a small metal binding protein that appears to 
act in the transport and/or sequestration of Cu (Lin and 
Culotta, 1995), also complements the absence of SOD1. 
All three gene products are clearly involved in metal ho- 
meostasis. Since SOD1 is very abundant in nervous tissue 
(0.5% of soluble protein; see Figure 1), the genetic evi- 
dence in yeast leads credence to the idea that FALS-linked 
SOD1 mutations adversely affect Cu homeostasis and 
thus lead to dysfunction and death of nerve cells. 
The most conspicuous pathology in the G37R mice is 
vacuolar degeneration of axons and dendrites of motor 
neurons that exists in presymptomatic mice. Because oxi- 
dative phosphorylation occurring in mitochondria is 
thought o generate high levels of intracellular f ee radicals 
(e.g., Richter et al., 1988; Luft, 1994), the vulnerability of 
mitochondria in the G37R mice might arise from locally 
generated free radicals. However, it is unexpected that 
mitochondria themselves are apparently a prominent ar- 
get for damage because SOD1 is localized in the cyto- 
plasm (Pardo et al., 1995) and mitochondria contain 
SOD2, which is encoded by a different nuclear gene (Crea- 
ganet al., 1973). Moreover, enhanced free radical-medi- 
ated damage is not an outcome expected from the signifi- 
cant elevation in SOD1 activity in the affected G37R mice. 
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The pathology seen in the G37R mice contrasts in two 
important ways from that reported for human disease. 
First, vacuolar degeneration has not been a well recog- 
nized component of motor neuron pathology in familial or 
sporadic ALS. More specificially, we have not seen these 
abnormalities in the few motor neurons remaining in the 
one end-stage case of a human G37R FALS patient avail- 
able to us (data not shown). Enlargement of mitochondria 
in hepatocytes has been reported in a few patients, but 
this was not seen in motor neurons (Hirano et al., 1984; 
Nakano et al., 1987). Changes in the activities of the mito- 
chondrial electron transport chain complex I have also 
been reported in FALS (Bowling et al., 1993), although 
this study could not distinguish between a specific effect 
on mitochondria nd a general loss from cell death. Sec- 
ond, neurofilamentous accumulations in cell bodies and 
proximal axons are infrequently present in affected mice, 
although they are a conspicuous feature of the pathology 
in SODl- l inked FALS (for example, for disease mediated 
by A4V [Hirano et al., 1984; T. Siddique, personal commu- 
nication] or I113T [G. Rouleau and A. Clark, personal com- 
munication]) and in sporadic ALS (Hirano, 1991). Although 
similar neurofilamentous masses resulting from overex- 
pression of wild-type NF-L (Xu et al., 1993) or NF-H (C6t~ 
et al., 1993) or expression of NF-L mutants (Lee et al., 
1994) can be primary causes of selective motor neuron 
death, they do not appear to play prominent roles in the 
G37R mice. 
A reasonable resolution to the differences in human pa- 
thology as compared with the G37R mice is that the pre- 
dominance of vacuoles containing degenerating mito- 
chondria and the minimal neurofi lamentous pathology in 
the mice may be related to an acceleration of the patho- 
genic process in mice by increasing the rate of mutant 
SOD 1-mediated damage with increased abundance of the 
mutant protein. Furthermore, the fact that vacuolation is 
observed in some nonneuronal cells in mice with the high- 
est levels of G37R accumulation implies that the target(s) 
of mutant SODl- induced damage cannot be exclusive to 
neurons. 
Although vacuolar abnormalities were not described in 
the initial report of one line of mice expressing a different 
FALS-linked SOD1 (G93A; Gurney et al., 1994), more re- 
cently, vacuolar changes in neurons have been observed 
in this transgenic line, but they have been interpreted to 
reflect alteration in rough endoplasmic reticulum (in peri- 
karya), followed by defects in mitochondria (Dal Canto and 
Gurney, 1994). This finding contrasts with the prominent 
dendritic and axonal vacuolation seen in all four of our 
affected G37R lines. Although our data do not eliminate 
a SOD1 mutant effect on the endoplasmic reticulum, the 
earliest and most prominent abnormality is the presence 
of vacuoles and altered mitochondria. 
In conclusion, the results of the present investigation of 
four lines of G37R mice proves that an aberrant property of 
the G37R SOD1 mutant is sufficient to cause progressive 
motor neuron disease, even in the presence of elevated 
SOD1 activity. These G37R mice should be useful in iden- 
tifying the pathogenetic mechanism(s) of disease and pro- 
vide a small animal model of the disease, which should 
facilitate the rapid testing of potential therapeutic ap- 
proaches for motor neuron disease. 
Experimental Procedures 
Construction of Transgenic Mice Expressing Wild-Type 
and Mutant Human SOD1 
A previously characterized plasmid, pHGSOD-SVneo (Epstein et al., 
1987), encoding a wild-type human SOD1 was used for the construc- 
tion of transgenic mice. This gene is contained within a 12 kb genomic 
DNA fragment hat was excised by EcoRI and BamHI, gel purified, 
and microinjected into hybrid (C57BL/6J x C3H/HeJ)F2 mouse em- 
bryos. The G37R mutation was engineered into the human SOD1 gene 
by PCR/oligonucleotide primer-directed mutagenesis strategy. In 
brief, a PstI-Xbal fragment (~ 2 kb) of pHuSOD1 encompassing the 
entire second exon was first subcloned into pBluescript vector. The 
G37R mutation was introduced by PCR using a mutagenic primer 
that spans codon 37 and a set of flanking primers complementary to 
sequences in the vector. The PCR product was then digested with 
Pstl and Xbal and subcloned into pBluescript. Potential clones were 
screened and confirmed by DNA sequencing of the entire exon 2 and 
flanking mRNA splicing signals. The complete gene was finally reas- 
sembled with an NdeI-Xbal subfragment containing the G37R muta- 
tion. The final 12 kb fragment containing the G37R mutation was ex- 
cised by EcoRI and BamHI and introduced into mouse embryos. 
Transgenic founder mice were identified by Southern blotting of DNA 
isolated from mouse tail (Xu et al., 1993), using the human SOD1 
cDNA as a probe. 
SDS-PAGE and Immunoblotting 
Total protein extracts from mouse tissues were homogenized in buffer 
containing 25 mM sodium phosphate (pH 7.2), 5 mM EGTA, 1% SDS, 
and 1 mM PMSF. After determining the protein concentration, 20 p.g 
of total protein for each tissue was loaded onto a 15% polyacrylamide 
gel, electrophoresed, and transferred onto nitrocellulose filters. En- 
dogenous mouse SOD1 and wild-type or mutant human SOD1 were 
detected using a recently characterized polyclonal antibody (Pardo et 
al., 1995) recognizing a common epitope of both mouse and human 
SOD1 followed by l~l-labeled protein A. Quantitative immunoblotting 
was performed using a dilution series of known amounts of purified 
human SOD1 (Sigma, St. Louis, MissOuri) as standards electropho- 
resed on the same blot. Signals were quantified using a Molecular 
Dynamics Phosphorlmager. 
SOD1 Activity Gels 
Mouse tissues were homogenized in buffer containing 20 mM Tris- 
CI (pH 7.2), 1 mM EDTA, and lO/o Triton X-100. After centrifugation 
at 10,000 x g for 5 min, the supernatant was electrophoresed on a 
7.5% polyacrylamide gel, and SOD1 activities were determined as 
previously reported (Beauchamp and Fridovich, 1971). Using a dilution 
series of known amounts of purified human SOD1 as standards, SOD1 
activity gels were quantified by using a Stratagene Eagle Eye II to 
digitize images. 
Histopathologlcal Analysis 
Mice anesthetized with an intraperitoneal injection of 4% chloral hy- 
drate were sacrificed by transcardiac perfusion with 0.1 M PBS (pH 
7.4), followed by 4°/0 paraformaldehyde in0.1 M PBS (pH 7.4). Brain, 
spinal cord, and other organs were removed and postfixed in the same 
fixative. Coronal sections of the brain and cross-sections of brainstem 
and spinal cord were embedded in paraffin, sectioned (10 p.m), and 
stained with hematoxylin and eosin, cresyl violet, Luxcl Fast Blue, 
and Bielschowski silver. Fresh skeletal muscle biopsies were obtained 
previous to fixation and frozen by immersion in isopentane cooled in 
liquid nitrogen. Sections (10 I~m) were cut and processed for NADH, 
ATPase (pH 4.4 and 9.4), Gomori trichmme, and acetylcholinesterase- 
silver (Dubowitz et al., 1973). 
Immunocytochemletry 
Deparaffinized sections (10 p.m) we re processed for i mmunocytochem- 
istry (peroxidase-antiperoxidase method) using antibodies recogniz- 
ing neurofilaments, microtubule-associated protein 2, glial fibrillary 
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protein, ubiquitin, and SOD1. The immune reaction was visualized 
with diaminobenzidine, and sections were counterstained with hema- 
toxylin. 
Electron Microscopy 
Anesthetized mice were perfused with 4% paraformaldehyde and 2% 
glutaraldehyde in 0.1 M PBS (pH 7.4). Tissues from brain, brainstem, 
spinal cord, dorsal root ganglia, ventral and dorsal root, and sciatic 
nerve were postfixed in the same fixative for 2 hr, washed several 
times in PBS, and postfixed with 1% osmium tetroxide for 2 hr. Subse- 
quently, tissues were washed again in PBS, dehydrated, and embed- 
ded in Epon. Thick (1 I~m) and thin (100 nm) sections were obtained 
and stained with toluidine blue and lead citrate/uranyl acetate, respec- 
tively. 
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